Profile: Insulet Corporation (PODD.O)

PODD.O on Consolidated Issue listed on NASDAQ Global Market

13.48USD
9 Feb 2010
Price Change (% chg)

$0.31 (+2.35%)
Prev Close
$13.48
Open
--
Day's High
$13.58
Day's Low
$12.97
Volume
245,222
Avg. Vol
239,093
52-wk High
$15.22
52-wk Low
$2.57

view overview for:

Insulet Corporation is a medical device company that develops, manufactures and markets insulin infusion system for people with insulin-dependent diabetes. The Company’s OmniPod Insulin Management System (OmniPod System) consists of its OmniPod disposable insulin infusion device and its handheld, wireless Personal Diabetes Manager. The United States Food and Drug Administration have approved the OmniPod System for sale in the United States.

The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a disposable insulin infusion device worn beneath clothing that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism and batteries, and the Personal Diabetes Manager (PDM), a handheld device that wirelessly programs the OmniPod with insulin delivery instructions, assists the patient with diabetes management and integrates a blood glucose meter. The OmniPod operates for at least 72 hours (but no more than 80 hours) after it is first activated. The OmniPod design reduces the size of the insulin delivery mechanism. The OmniPod consists of a hands-free cannula insertion system. Cannula insertion is activated wirelessly using the PDM, so the patient never sees or handles an introducer needle.

The Company competes with Medtronic, Inc., Johnson & Johnson, Smiths Medical MD, Inc., F. Hoffmann-La Roche, Ltd, Medingo, Nilimedix, Sensile Medical, M2 Medical, Phluid Corporation, Seattle Medical, Starbridge Medical Systems, Novo Nordisk A/S and Abbott Laboratories.

Company Address

Insulet Corporation

9 Oak Park Drive
Bedford   MA   01730
P: +1781.4575000
F: +1781.4575011

view overview for: